BioCentury
ARTICLE | Finance

European beachhead

Epirus thinks reverse merger with Zalicus will open up Europe for biosimilars

April 21, 2014 7:00 AM UTC

Epirus Biopharmaceuticals Inc. hopes its $36 million series B round and reverse merger with Zalicus Inc. (NASDAQ:ZLCS) will enable the biosimilars company to crack the European market.

The combined public company will retain Epirus' name and focus on development of BOW015, a biosimilar of autoimmune drug Remicade infliximab from Johnson & Johnson (NYSE:JNJ) and Merck & Co. Inc. (NYSE:MRK). Early next year, Epirus plans to start a European Phase III trial in rheumatoid arthritis (RA)...